Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-02-13
2007-02-13
Lankford, L Blaine (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S654000, C514S579000, C514S699000, C435S004000, C424S093700
Reexamination Certificate
active
10002854
ABSTRACT:
This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.
REFERENCES:
patent: 5686574 (1997-11-01), Moore et al.
patent: 5756448 (1998-05-01), Moore et al.
patent: 5981599 (1999-11-01), Moe et al.
patent: 6184254 (2001-02-01), Bukoski et al.
patent: 0256989 (1988-02-01), None
patent: 0852144 (1998-07-01), None
patent: WO 01/83546 (2001-11-01), None
Yamaguchi et al. J of Bone and Mineral Research vol. 13 (10) 1998 pp. 1530-1538.
Adams, GB, et al., “Bone mineral contributes to Bone Marrow Hematopoiesis through the calcium sensing receptor.”American Society for Hematology, 2001 Annual Meeting, Orlando, FL, Dec. 7-11, 2001, Abstract Only.
Aida, K., et al., Biochem. Biophys. Res. Commun. Sep. 14, 1995; 214(2):524-9 abstract only.
Brundage RA, et al.,ScienceNov. 1, 1991;254(5032):703-6. Abstract Only.
Burger JA, et al.BloodDec. 1, 1999;94(11):3658-67. Abstract Only.
Catapano AL.,Eur Heart JJan. 1997; 18 Suppl A:A80-6. Abstract Only.
Chattopadhyay N, et al.,Brain Res Mol Brain ResAug. 15, 2001;92(1-2):172-6. Abstract Only.
Elferink JG, et al.,Chem Biol InteractMar. 30, 1995;95(1-2):203-14. Abstract Only.
Elferink, JG et al.,Biochem Biophys Res Commun. 1992, 182(2):864-9. Abstract Only.
Ferrari MB, et al.,Dev BiolSep. 15, 1999;213(2):269-82. Abstract Only.
Ganju RK, et al.,J Biol ChemSep. 4, 1998;273(36):23169-75.
Genbank Accession D50855 Human mRNA for Ca-sensing receptor, complete eds. Jun. 23, 1999.
Gerszten RE, et al.,NatureApr. 22, 1999;398(6729):718-23, Abstract Only.
Guinamard R., et al.,J Exp MedMay 3, 1999;189(9):1461-6. Abstract Only.
Henry PD.,Clin Invest MedNov. 1987;10(6):601-5. Abstract Only.
Herbette LG, et al.,Blood Press Suppl1998;2:10-7. Abstract Only.
House MG, et al.,J Bone Miner ResDec. 1997;12(12):1959-70.
Huang HJ, et al.,J Leukoc BiolMay 1997;61(5):624-9 Abstract Only.
Jordan NJ, et al.,J Clin InvestOct. 1999;104(8):1061-9.
Kim CH, et al.,J Clin InvestDec. 1999;104(12):1751-9.
Laster SM, et al.,J Immunol. Jul. 1, 1988, 141(1):221-7 Abstract Only.
Liu, L. et al.,J ImmunolNov. 15, 1999;163(10):5649-55. Abstract Only.
Marasco WA, et al.,Am J PatholMar. 1980;98(3):749-68. Abstract Only.
Marks PW, et al.,J Cell BiolJan. 1990;110(1):43-52.
Marra, F., et al.,Hepatology. Jan. 1999;29(1):140-8. Abstract Only.
McColl SR, et al.,J ImmunolSep. 1, 1999;163(5):2829-35. Abstract Only.
Meshulam T, et al.,J Immunol. Sep. 15, 1986;137(6):1954-60.
Mishima T, et al.,Clin Exp MetastasisAug 1998;16(6):541-50. Abstract Only.
Murdoch C, et al.,CytokineSep. 1999;11(9):704-12. Abstract Only.
Murdoch C, et al.,ImmunologySep. 1999;98(1):36-41. Abstract Only.
Nayler WG.,J. Cardiovasc Pharmacol1999;33 Suppl 2:S7-11. Abstract Only.
Nikol S, et al.,Eur Heart JJan. 1997;18 Suppl A:A105-9. Abstract Only.
Olszak IT, et al.,J Clin InvestMay 2000;105(9):1299-1305.
Paoletti R, et al.,Am J CardiolNov. 20, 1990;66(18):28H-31H. Abstract Only.
Paoletti R, et al.,Ann N Y Acad Sci1988;522:390-8. Abstract Only.
Paoletti R, et al.,J Cardiovasc Pharmacol1995;25 Suppl 3:S6-10. Abstract Only.
Raicu M, et al.,J Submicrosc Cytol PatholJul. 1997;29(3):317-28 Abstract Only.
Riviere C., et al.,BloodMar. 1, 1999;93(5):1511-23, Abstract Only.
Schmitz G, et al.AtherosclerosisJun. 1991;88(2-3):109-32 Abstract Only.
Schwartz J.,Fundam Clin Pharmacol1988;2(2):103-20. Abstract Only.
Schweizer RC, et al.,J Leukoc BiolMar. 1996;59(3):347-56.
Shi H, et al.,FASEB JMar. 1996;10(4):491-501.
Sperling RI, et al.,J Clin InvestFeb. 1993;91(2):651-60. Abstract Only.
Sugimoto T, et al.,J Bone Miner ResDec. 1993;8(12):1445-52. Abstract Only.
Suzuki H, et al.,Int ImmunolMay 1997;9(5):763-9. Abstract Only.
Tulenko TN, et al.,Int J CardiolDec. 31, 1997;62 Suppl 2:S55-66. Abstract Only.
Weinstein DB, et al.,Am J CardiolJan. 30, 1987;59(3):163B-172B. Abstract Only.
Yamaguchi T, et al.,EndocrinologyAug. 1998;139(8):3561-8. Abstract Only.
Yamaguchi T, et al.,J Bone Miner ResSep. 1998;13(9):1390-7. Abstract Only.
Yamaguchi T., et al.,Adv Pharmacol2000;47:209-53.
Youn BS., et al.,BloodOct. 1, 1999;94(7):2533-6. Abstract Only.
Zhou X.,Zhonghua Yi Xue Za ZhiJul. 1992;72(7):424-6, 447 Abstract Only.
Petrel, et al., “Positive and Negative Allosteric Modulators of the Ca2+-sensing Receptor Interact within Overlapping but Not Identical Binding Sites in the Transmembrane Domain”, The Journal of Biological Chemistry, vol. 279, (18), Issue of Apr. 30, pp. 18990-18997, 2004.
Nemeth, et al., “Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCI”, The Journal of the Pharmacology and Experimental Therapeutics, vol. 308 (2), pp. 627-635, 2004.
Gowen, et al., “Antagonizing the Parathyroid Calcium Receptor Stimulates Parethyroid Hormone Secretion and Bone Formation in Osteopenic Rats”, J. Clin. Invest. 105:1595-1604, 2000.
Brown Edward M.
Olszak Ivona T.
Poznansky Mark C.
Scadden David T.
Edwards Angell Palmer & & Dodge LLP
Lankford L Blaine
Leahy Amy
The Brigham and Women's Hospital, Inc.
The General Hospital Corporation
LandOfFree
CaR receptor as a mediator of migratory cell chemotaxis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CaR receptor as a mediator of migratory cell chemotaxis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CaR receptor as a mediator of migratory cell chemotaxis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873768